'Breda et al. (2) provide a proof of principle of in vivo genetic engineering of HSPCs in the bone marrow of mice by leveraging transient delivery of mRNA through lipid nanoparticles (LNPs) functionally coupled to antibodies that target HSPCs.'

https://www.science.org/doi/10.1126/science.adj0997?utm_campaign=SciMag&utm_source=Twitter&utm_medium=ownedSocial